
|Videos|March 1, 2019
Evaluating the Role of CAR T Cells in Multiple Myeloma
Author(s)Gareth Morgan, MD
Gareth Morgan, MD, discusses where he sees the field headed for the treatment of patients with multiple myeloma.
Advertisement
Gareth Morgan, MD, director of Myeloma Research at NYU Langone's Perlmutter Cancer Center, discusses where he sees the field of CAR T cells headed for the treatment of patients with multiple myeloma.
While there are many treatment options available, these patients are still relapsing, Morgan says. The treatments also have many side effects, so cellular therapy could replace many of the current therapies that are available.
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Targeted Oncology - Immunotherapy, Biomarkers, and Cancer Pathways
1
FDA Approves Iberdomide, the First CELMoD for Relapsed/Refractory Multiple Myeloma
2
Zipalertinib Combo Meets PFS End Point in First-Line EGFR Exon 20+ NSCLC
3
FDA Grants Breakthrough Device Designation to Blood-Based Lung Cancer Screening
4
Talquetamab Shows Durable Responses in R/R MM at 3-Year Follow-Up
5



































